Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Liver cancer initiation requires translational activation by an oncofetal regulon involving LIN28 proteins
Meng-Hsiung Hsieh, … , John T. Powers, Hao Zhu
Meng-Hsiung Hsieh, … , John T. Powers, Hao Zhu
Published June 14, 2024
Citation Information: J Clin Invest. 2024;134(15):e165734. https://doi.org/10.1172/JCI165734.
View: Text | PDF
Research Article Hepatology

Liver cancer initiation requires translational activation by an oncofetal regulon involving LIN28 proteins

  • Text
  • PDF
Abstract

It is unknown which posttranscriptional regulatory mechanisms are required for oncogenic competence. Here, we show that the LIN28 family of RNA-binding proteins (RBPs), which facilitate posttranscriptional RNA metabolism within ribonucleoprotein networks, is essential for the initiation of diverse oncotypes of hepatocellular carcinoma (HCC). In HCC models driven by NRASG12V/Tp53, CTNNB1/YAP/Tp53, or AKT/Tp53, mice without Lin28a and Lin28b were markedly impaired in cancer initiation. We biochemically defined an oncofetal regulon of 15 factors connected to LIN28 through direct mRNA and protein interactions. Interestingly, all were RBPs and only 1 of 15 was a Let-7 target. Polysome profiling and reporter assays showed that LIN28B directly increased the translation of 8 of these 15 RBPs. As expected, overexpression of LIN28B and IGFBP1-3 was able to genetically rescue cancer initiation. Using this platform to probe components downstream of LIN28, we found that 8 target RBPs were able to restore NRASG12V/Tp53 cancer formation in Lin28a/Lin28b-deficient mice. Furthermore, these LIN28B targets promote cancer initiation through an increase in protein synthesis. LIN28B, central to an RNP regulon that increases translation of RBPs, is important for tumor initiation in the liver.

Authors

Meng-Hsiung Hsieh, Yonglong Wei, Lin Li, Liem H. Nguyen, Yu-Hsuan Lin, Jung M. Yong, Xuxu Sun, Xun Wang, Xin Luo, Sarah K. Knutson, Christina Bracken, George Q. Daley, John T. Powers, Hao Zhu

×

Figure 2

Lin28a and Lin28b are both required for liver cancer development.

Options: View larger image (or click on image) Download as PowerPoint

Lin28a and Lin28b are both required for liver cancer development.
(A) S...
(A) Schematic for HDT of transposons in Tp53-KO and Lin28a/Lin28b/Tp53-TKO mice. (B) Representative gross images (left) and liver-to-body weight ratios (right) of Tp53-KO (n = 14) and Lin28a/Lin28b/Tp53-TKO (n = 8) mice receiving transposons carrying NRASG12V for 7 weeks (P105). Scale bars: 1 cm; 5 mm (right panels). (C) IHC shows NRAS and LIN28B expression in early lesions of Tp53-KO and Lin28a/Lin28b/Tp53-TKO mice that had NRASG12V injected 2 weeks prior (P70). Scale bars: 50 μm. (D) Representative gross images (left) and liver-to-body weight ratios (right) of Tp53-KO (n = 7) and Lin28a/Lin28b/Tp53-TKO (n = 3) mice receiving transposons carrying AKT for 7 weeks (P105). Scale bars: 1 cm; 7.5 mm (right panels). (E) Representative gross images (left) and liver-to-body weight ratios (right) of Tp53-KO (n = 3) and Lin28a/Lin28b/Tp53-TKO (n = 3) mice receiving transposons carrying CTNNB1N90 and YAPS137A for 7 weeks (P105). Scale bars: 1 cm; 5 mm (right panels). **P < 0.01.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts